COMP <GO>
EOLS vs CTMX // PIOTROSKI F-SCORE QUALITY
Evolus Inc. (NASDAQ) VS. CytomX Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: EOLS 6
— CTMX 2
▲ PIOTROSKI F-SCORE QUALITY LEADER: EOLS
LAST: $7.52 (-1.51%) • MKT CAP: $496.7M
piotroski-score
4/9
LAST: $2.29 (-2.97%) • MKT CAP: $499.0M
piotroski-score
1/9
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (EOLS VS. CTMX)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | EOLS | CTMX | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 66.30% | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | -20.50% | -14.50 | CTMX | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -9.20% | -15.19% | +5.99 | EOLS | /fcf-yield <GO> |
| Operating Margin | -11.00% | -29.30% | +18.30 | EOLS | /operating-margins <GO> |
| Net Profit Margin | -17.40% | -22.80% | +5.40 | EOLS | /net-margins <GO> |
| Revenue Growth (YoY) | 11.60% | -44.80% | +56.40 | EOLS | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 0.20 | 0.20 | 0.00 | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality ACTIVE | 4/9 | 1/9 | +3.00 | EOLS | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 46.1 | 42.7 | +3.43 | EOLS | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $496.7M | $499.0M | -$2.3M | CTMX | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | EOLS REV | CTMX REV | EOLS GROSS % | CTMX GROSS % | EOLS FCF | CTMX FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $297.2M | $76.2M | 66.3% | — | -$45.7M | -$75.8M |
| FY 2024 | $266.3M | $138.1M | 68.5% | — | -$19.5M | -$86.5M |
| FY 2023 | $202.1M | $101.2M | — | — | -$34.0M | -$56.0M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
EOLS // BETA —
CTMX // BETA —